^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Published date:
01/12/2021
Excerpt:
...Have T790M-positive status using a test validated and performed locally after disease progression on EGFR tyrosine kinase inhibitor (TKI) treatment...
Trial ID:
Source:
Title:
Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer
Published date:
10/12/2020
Excerpt:
Ramucirumab plus osimertinib demonstrated encouraging safety and antitumor activity in T790M-positive EGFR-mutant NSCLC.
DOI:
10.1158/1078-0432.CCR-20-1690
Trial ID:
Source:
Title:
Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.
Published date:
05/16/2018
Excerpt:
...Phase 1study (NCT02789345) enrolled pts with T790M-positive EGFR-mutant...Fifteen pts remain on study drug. ORR was 76% (19/25), with CR 4% (1/25), PR 72% (18/25), SD 16% (4/25), PD 4% (1/25), and non-evaluable 4% (1/25). DCR was 92%...DOR rate at 6 months was 81.6% (90% CI: 59.0, 92.4)...PFS rate at 6 months was 64.0%...Ram + Osi demonstrated encouraging antitumor activity. The safety profile was consistent with monotherapy for each drug, with no additive toxicities.
DOI:
10.1200/JCO.2018.36.15_suppl.9053
Trial ID:
